PRODUCT INFORMATION



Emvododstat

Item No. 36877

CAS Registry No.: 1256565-36-2

Formal Name: (1S)-6-chloro-1,3,4,9-tetrahydro-1-(4-

methoxyphenyl)-2H-pyrido[3,4-b]indole-2-


carboxylic acid, 4-chlorophenyl ester

Synonym: PTC-299

MF: $C_{25}H_{20}CI_2N_2O_3$

FW: 467.3 **Purity:** λ_{max} : 229 nm UV/Vis.: Supplied as: A solid -20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Emvododstat is supplied as a solid. A stock solution may be made by dissolving the emvododstat in the solvent of choice, which should be purged with an inert gas. Emvododstat is soluble in the organic solvent DMSO at a concentration of approximately 50 mg/ml.

Description

Emvododstat is an inhibitor of dihydroorotate dehydrogenase (DHODH).1 It inhibits DHODH by 89% in HeLa cells when used at a concentration of 100 nM. Emvododstat inhibits hypoxia-induced VEGF-A synthesis in HeLa cells (EC₅₀ = 1.64 nM). It inhibits viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV) replicon genotype 1b, poliomyelitis virus, Rift Valley fever (RVF) virus, and Ebola virus in Vero, Huh7, HeLa, HeLa, and Vero 76 cells, respectively $(EC_{50}s = 2.6, 36, 0.57, 13, and 9.1 \text{ nM}, respectively})^2$ Emvododstat inhibits production of IL-17F and IL-17A induced by CD3 and CD28 in Th17 cells in a concentration-dependent manner.

References

- 1. Cao, L., Weetall, M., Trotta, C., et al. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. Mol. Cancer Ther. **18(1)**, 3-16 (2019).
- 2. Luban, J., Sattler, R.A., Mühlberger, E., et al. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res. 292, 198246 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM